PMID: 6986476Feb 1, 1980Paper

Post-transplantation pyelonephritis: factors producing low patient and transplant morbidity

The Journal of Urology
J C PearsonO Salvatierra

Abstract

A retrospective study of 1,100 consecutive renal transplantations done on 959 patients revealed postoperative pyelonephritis in 15 patients, 14 of whom were women. Sixteen of the 20 episodes of pyelonephritis were caused by Escherichia coli and only 4 episodes occurred within the first year after transplantation, thus revealing the crucial differentiation from a rejection episode. When the etiology of the original renal failure was pyelonephritis the incidence of pyelonephritis in the transplanted kidneys was high. This high incidence also was true for cases associated with post-transplantation urological complications. When the etiology of renal failure was diabetes or polycystic renal disease, or when urologic abnormalities pre-existed the incidence of pyelonephritis was low. No transplant or patient loss was caused by post-transplantation pyelonephritis, probably because of prompt, correct diagnosis and a low urological complication rate.

References

Apr 1, 1977·The Journal of Urology·O SalvatierraN J Freduska
Aug 25, 1977·The New England Journal of Medicine·T H MathewP Vikraman
Oct 1, 1977·Annals of Surgery·O SalvatierraF O Belzer
Oct 5, 1974·Lancet·R J HamshereR Shackman
Nov 1, 1973·Annals of Surgery·G M HrickoR E Wilson
Jun 1, 1973·Urology·F B MahonD T Uehling
Oct 1, 1974·The Journal of Urology·O SalvatierraF O Belzer

❮ Previous
Next ❯

Citations

Nov 10, 2000·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·B RanchinP Cochat
Sep 1, 1985·Infection·V PrátM Liska
Dec 1, 1986·The Journal of Urology·T WeinsteinJ Levi
Oct 6, 1997·Infectious Disease Clinics of North America·N E Tolkoff-Rubin, R H Rubin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.